Insights from Matilde Thye Kveiborg, Director of Medical Writing and Tanja Jensen, Senior Medical Writer

Rare diseases are often multifaceted, and a single endpoint is often not sufficient to fully describe treatment

Radiopharmaceutical therapy utilizes radioactive atoms to target and precisely treat cancer cells.

At the bottom of the EBM hierarchy, mechanistic evidence is not highly valued by the HTA bodies responsible for…

Lionel RIOU FRANÇA, Chief Scientific Officer, was involved in two analyses involving patients with Late-Onset Pompe…

Cell and gene therapies are multiplying, and with them the hopes of patients, their families, and healthcare professionals…

Cmed and Larix fully integrate into Aixial Group Press release – May 30th 2023 Following its acquisition of Larix in…

This case study looks at the challenges that arose in a Phase I First In Human trial for the progressive Wilson’s Disease

Cell & Gene Therapy: Safety and Clinical Activity in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Case…

Rare Diseases: Phase II Pediatric Study with Selected Metabolic Disorders Case study Aixial Group is currently working on a Phase…

Data Science & Analytics: Combining A Phase I Study with an On-Going Observational Study Case study This case study looks…

Early Phase Oncology: First-In-Human Study Of An Antibody-Drug Conjugate In Breast Cancer Case study For a First In Human study,…